UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
For the month of August 2025
Commission File Number: 001-41425
金太阳健康科技集团有限公司
(Translation of registrant’s name into English)
Golden Sun Health Technology Group Limited
Room 503, Building C2, No. 1599
Xinjinqiao Road, Pudong New Area
Shanghai, China
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
INCORPORATION BY REFERENCE
This Current Report on Form 6-K shall be deemed
to be incorporated by reference into the registration statement on Form
F-1, as amended (Registration Number: 333-285857) of Golden Sun Health Technology Group Limited, a Cayman Islands exempted company
(the “Company”), declared effective by the Securities and Exchange Commission (“SEC”) on March 25,
2025 (“Registration Statement”), and into each prospectus or prospectus supplement outstanding under the Registration
Statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act
of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
As previously reported in the Current Report on
Form 6-K filed with the SEC on December 6, 2024 (“December 2024 6-K”), pursuant to a certain Securities Purchase Agreement
(the “SPA”), dated October 28, 2024, entered into by and between the Company and two accredited investors (the “Investors”),
the Company has issued and sold to the Investors i) a Convertible Note (the “Note”) in the aggregate principal amount
of $5,000,000 and ii) a Warrant (the “Warrant”) to purchase an amount of Class A ordinary shares, $0.005 par
value per share, (the “Class A Ordinary Shares”) of the Company as calculated in accordance per the SPA, at the closing
held on December 3, 2024.
As previously reported in the Current Report on
Form 6-K filed with the SEC February 28, 2025, the Company received a written notification from the staff (the “Staff”)
of the Nasdaq Capital Market LLC (“Nasdaq”), dated February 24, 2025, that the Company does not meet the minimum shareholders’
equity of $2.5 million under the Nasdaq Listing Rule 5550(b)(1) (the “Shareholder Equity Rule”) for continued listing.
The Company subsequently submitted a plan for compliance to the Staff to regain compliance with the Shareholder Equity Rule.
On August 22, 2025, the Investors fully
exercised the Warrant and converted all outstanding principal and interest under the Note into Class A Ordinary Shares, resulting in
the issuance of an aggregate 6,747,926 Class A Ordinary Shares to such Investors.
As such, the Note and the Warrant are no
longer outstanding. The carrying value of the Note and the Warrant, with an aggregated amount of approximately $9.4 million as of March 31, 2025, will
be reclassified to the Company’s total equity as of August 25, 2025. Therefore, the Company believes that, as of the date of
this Current Report on Form 6-K, it satisfies the Shareholder Equity Rule for continued listing on the Nasdaq Capital Market. The
Company is awaiting a formal compliance determination from the Staff and will provide an update upon receipt of such
determination.
The above descriptions of the SPA, Warrant and
the Note are not complete. Please refer to the December 2024 6-K for the full text of the forms of such documents.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
| |
Golden Sun Health Technology Group Limited |
| |
|
|
| |
By: |
/s/ Xueyuan Weng |
| |
|
Name: |
Xueyuan Weng |
| |
|
Title: |
Chief Executive Officer |
Date:
August 25, 2025
